Topical and transdermal product development company Skinvisible (OTCQB: SKVI) is targeting the pharmaceutical industry with its proprietary drug delivery system, Invisicare. Invisicare improves the delivery of ingredients to and through the skin. An article discussing this reads: “Skinvisible has developed over 40 product formulations using Invisicare both in the medical and skincare markets, in addition to being granted 14 patents. The company is focused on licensing its formulations and Invisicare to other companies in the pharmaceutical and cosmeceutical industries. The company’s business model emphasizes four revenue streams that include fees for new product development, license fees, sales of branded products, and on-going royalty fees based on a licensee’s sales.”
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Read More
Skinvisible, Inc. (SKVI) Advances Invisicare Delivery System
